Chenodal Related Published Studies
Well-designed clinical trials possibly related to Chenodal (Chenodiol)
High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. [2011.09]
Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis. [2010.11]
Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. [2010.07]
Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. [2010.02]
Bile acid changes after high-dose ursodeoxycholic acid treatment in primary
sclerosing cholangitis: Relation to disease progression. [2010]
Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on
intestinal transit and bowel function. [2010]
Removal of bile acids by two different extracorporeal liver support systems in acute-on-chronic liver failure. [2007.03]
Other possibly related research studies
Pharmacotherapy of cholestatic liver diseases. [2010.06]
Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. [2010.08]
Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease. [2010.06.25]
Cerebrotendinous xanthomatosis presenting with severe externalized disorder: improvement after one year of treatment with chenodeoxycholic Acid. [2010.04]
Bile acids modulate glucocorticoid metabolism and the hypothalamic-pituitary-adrenal axis in obstructive jaundice. [2010.05]
Bile acids for liver-transplanted patients. [2010.03.17]
Salivary chenodeoxycholic acid and its glycine-conjugate: their determination method using LC-MS/MS and variation of their concentrations with increased saliva flow rate. [2010.04]
Plasma bile acid concentrations in patients with human immunodeficiency virus infection receiving protease inhibitor therapy: possible implications for hepatotoxicity. [2010.01]
Variable clinical spectrum of the most common inborn error of bile acid metabolism--3beta-hydroxy-Delta 5-C27-steroid dehydrogenase deficiency. [2010.01]
Nutritional approaches to prevention and treatment of gallstones. [2009.09]
Albumin dialysis molecular adsorbents recirculating system: impact of dialysate albumin concentration on detoxification efficacy. [2009.10]
The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. [2009.12]
Effect of mitiglinide on Streptozotocin-induced experimental type 2 diabetic rats: a urinary metabonomics study based on ultra-performance liquid chromatography-tandem mass spectrometry. [2009.11.01]
Relative inhibitory activity of bile acids against 12-O-tetradecanoylphorbol-13-acetate-induced inflammation, and chenodeoxycholic acid inhibition of tumour promotion in mouse skin two-stage carcinogenesis. [2009.08]
Cerebrotendinous xanthomatosis (CTX): a treatable lipid storage disease. [2009.09]
[Expression and regulation of megalin in gallbladder mucosa associated with cholesterol gallstone disease] [2009.04.28]
Protective effects of glycoursodeoxycholic acid in Barrett's esophagus cells. [2010.02]
Regulation of diurnal variation of cholesterol 7alpha-hydroxylase (CYP7A1) activity in healthy subjects. [2010]
Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. [2009.01]
Cefotaxime pharmacokinetics after oral application in the form of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate microvesicles in rat. [2009.01]
Bile acids inhibit duodenal secretin expression via orphan nuclear receptor small heterodimer partner (SHP). [2009.07]
Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin. [2009.05]
The mechanism of the cholesterol-lowering effect of water-insoluble fish protein in ovariectomised rats. [2009.09]
Tauroursodeoxycholic acid prevents E22Q Alzheimer's Abeta toxicity in human cerebral endothelial cells. [2009.03]
Bear bile: dilemma of traditional medicinal use and animal protection. [2009.01.12]
Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. [2009.01]
Low retinol levels differentially modulate bile salt-induced expression of human and mouse hepatic bile salt transporters. [2009.01]
Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy. [2009.03]
The influence of 3alpha,7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. [2008.07]
Association between Fecal Bile Acids and Colorectal Cancer: A Meta-analysis of Observational Studies. [2008.10.31]
Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. [2008.03]
The synthesis of MP-CDCA conjugates and dissolution kinetics of model cholesterol gallstones. [2008.09]
Tauroursodeoxycholic acid preservation of photoreceptor structure and function in the rd10 mouse through postnatal day 30. [2008.05]
TUDCA prevents cholestasis and canalicular damage induced by ischemia-reperfusion injury in the rat, modulating PKCalpha-ezrin pathway. [2008.08]
Tauroursodeoxycholic acid and secondary damage after spinal cord injury in rats. [2008.06]
Tauroursodeoxycholic acid reduces bile acid-induced apoptosis by modulation of AP-1. [2008.02.29]
Cerebrotendinous xanthomatosis: a treatable cause of metabolic ataxia. [2007.09]
Effect of dietary inclusion of Lactobacillus acidophilus ATCC 43121 on cholesterol metabolism in rats. [2007.04]
Spectral-resolved gene technology for multiplexed bioluminescence and high-content screening. [2008.01.01]
Beneficial effects of hydrocortisone in induced acute pancreatitis of rats. [2007.10.20]
Ethanol stimulates bile acid formation in primary human hepatocytes. [2007.12.28]
Bile acids for viral hepatitis. [2007.10.17]
Subcutaneous vitamin E ameliorates liver injury in an in vivo model of steatocholestasis. [2007.08]
Bile acids promote the expression of hepatitis C virus in replicon-harboring cells. [2007.09]
[Cerebrotendinous xanthomatosis] [2007.07.29]
Can pigment gallstones be induced by biliary stricture and prevented by medicine in Guinea pigs? [2007.05.21]
Rifampicin-induced CYP3A4 activation in CTX patients cannot replace chenodeoxycholic acid treatment. [2007.07]
[Preparation and antitussive, expectorant and antiasthmatic activities of verticinone-bile acids salts] [2007.03]
Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3alpha,7alpha-dihydroxy-12-oxo-5beta-cholanate, in healthy and diabetic rats. [2007.01]
Bile acids and lipoprotein metabolism: effects of cholestyramine and chenodeoxycholic acid on human hepatic mRNA expression. [2007.06.08]
A new oral formulation for the release of sodium butyrate in the ileo-cecal region and colon. [2007.02.21]
A novel chenodeoxycholic derivative HS-1200 enhances radiation-induced apoptosis in MCF-7 cells. [2007.04]
Improvement of low bioavailability of a novel factor Xa inhibitor through formulation of cationic additives in its oral dosage form. [2011.12.15]
Profile of serum bile acids in noncholestatic volunteers: gender-related differences in response to fenofibrate. [2011.08]
Neuromuscular abnormality and autonomic dysfunction in patients with cerebrotendinous xanthomatosis. [2011.05.31]
Tauroursodeoxycholic acid prevents retinal degeneration in transgenic P23H rats. [2011.07.01]
Low levels of bile acids increase bacterial uptake in colonic biopsies from patients with collagenous colitis in remission. [2011.04]
Farnesoid X receptor agonists for primary biliary cirrhosis. [2011.05]
Endoplasmic reticulum stress is a mediator of posttransplant injury in severely steatotic liver allografts. [2011.02]
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. [2011.04]
The chemical chaperones tauroursodeoxycholic and 4-phenylbutyric acid accelerate thyroid hormone activation and energy expenditure. [2011.02.04]
Clinical relevance and neurophysiological correlates of spasticity in cerebrotendinous xanthomatosis. [2011.05]
Liver X receptor agonist methyl-3beta-hydroxy-5alpha,6alpha-epoxycholanate attenuates atherosclerosis in apolipoprotein E knockout mice without increasing plasma triglyceride. [2010]
The relationship between postprandial bile acid concentration, GLP-1, PYY and ghrelin. [2011.01]
The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice. [2010.10.08]
Synthesis and in vitro evaluation of gabapentin prodrugs that target the human apical sodium-dependent bile acid transporter (hASBT). [2011.03]
A microfluidic approach for in vitro assessment of interorgan interactions in drug metabolism using intestinal and liver slices. [2010.10.21]
Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. [2010.10]
Synergy of combined doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. [2010.07.30]
Molecular genetic and bile acid profiles in two Japanese patients with 3beta-hydroxy-DELTA5-C27-steroid dehydrogenase/isomerase deficiency. [2010.09]
Titration of bile acid supplements in 3beta-hydroxy-Delta 5-C27-steroid dehydrogenase/isomerase deficiency. [2010.06]
Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR/RXR-dependent and independent mechanisms. [2010.08]
Cerebrotendinous xanthomatosis: a treatable neurodegenerative disease. [2009.10]
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. [2010.04]
High-dose ursodeoxycholic acid is associated with the development of colorectal
neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. [2011]
Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue
insulin sensitivity in obese men and women. [2010]
Bile acids for liver-transplanted patients. [2010]
|
